FDA Approves INFLECTRA™ (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications
Go back to FDA Approves INFLECTRA™ (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications| Pfizer Inc. (NYSE: PFE) | Delayed: 24.90 -0.18 (0.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.08 | 52 Week High | $37.39 | |||
| Open | $24.99 | 52 Week Low | $28.25 | |||
| Day High | $25.24 | P/E | 15.09 | |||
| Day Low | $24.78 | EPS | $1.65 | |||
| Volume | 11,726,110 | |||||
